First 10 runs free
    Intelligence Feed event · Policy · 2026-10-27

    Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC

    Question

    Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC

    Direct answer

    Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-27
    Published
    2026-10-27
    Revision
    1 · 2026-10-27

    Cite as: Market Ontology, “Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC”, revision 1, evidence through 2026-10-27. https://marketontology.com/market-events/2026-10-27/bristol-myers-phase-3-oncology-trial-doubles-progression-free-survival-in-nsclc-bda72c

    POLICY
    Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC
    Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.
    BMY
    Impact
    71
    OCT 27
    SIG
    75%
    BMY
    Bristol Myers Phase 3 oncology trial doubles progression-free survival in NSCLC
    Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.
    → Superior oncology progression-free survival data enhances probability of regulatory approval and extends commercial patent cash flows for BMY.
    Impact
    Bristol Myers Squibb published Phase 3 trial data evaluating its experimental compound izalontamab brengitecan (iza-bren) in non-small cell lung cancer patients. The study demonstrated a progression-free survival of 11.1 months compared with 5.7 months for conventional chemotherapy cohorts, establishing a significant therapeutic differential.
    Affected
    BMY
    Transmission
    Superior oncology progression-free survival data enhances probability of regulatory approval and extends commercial patent cash flows for BMY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYoncology product commercial terminal value expansionUp1-4wPhase 3 clinical trial demonstrated progression-free survival improvement to 11.1 months from 5.7 months.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards